Akebia Therapeutics (AKBA) Misses Q2 EPS by 9c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.60), $0.09 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.81 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)